Curiva

Founders - use our current benchmark data to help raise your next VC round. Broken out into 25th, 50th, and 75th percentiles so you can place your fundraise within the broad current market. 𝗩𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻𝘀 • All numbers in the chart below are post-money valuations for primary rounds in Q3 2024. • Solid growth in Seed and Series A valuations from Q2. 𝗖𝗮𝘀𝗵 𝗥𝗮𝗶𝘀𝗲𝗱 • All numbers reflect the total amount raised in a given round. • Rounds have gotten larger at the 50th pct over the past year. 𝗗𝗶𝗹𝘂𝘁𝗶𝗼𝗻 • Percentages in the chart reflect the total equity sold to investors in the round. For SAFE rounds, it reflects the expected ownership at conversion given the valuation cap. • Dilution is calculated for each round independently - so you can't just read across the median valuation and round size to get the dilution figure! Other people will have different definitions of "pre-seed" - I get it! Amount raised in a SAFE round is the biggest determinant of the valuation cap. Also good to note that some of the pre-seed raises will probably end up raising more money on the same valuation cap. That part of the market is tricky. 𝗞𝗲𝘆 𝘁𝗵𝗶𝗻𝗴𝘀 𝘁𝗼 𝗸𝗻𝗼𝘄 𝗮𝗯𝗼𝘂𝘁 𝗤𝟯 1. Okay quarter. $20B invested into Carta startups, little less than Q2, little more than Q1. 2. Down rounds still hovering around 20% of all rounds. Still more kludge to work through from the boom times. 3. Dilution continues to center around 20% in Seed and Series A. 4. Time between rounds notched down for Seed to A, but up for A to B. Still good to plan for longer than you expect. 5. M&A bounceback? 170 companies acquired last quarter, the highest since 2022. Our full State of Private Markets report for Q3 is now live. Link in comments for the full report. If you want this graphic for your industry, give me shout that out in the comments below. Here's to a strong fundraising close & a better 2025! If you’d like more of our data in your inbox, subscribe today: https://lnkd.in/gNa_Dk-F

Day 2 #ZGI International #Accelorator in #SiliconValley #Networking Event We headed over to Nixon Peabody LLP as they hosted the live episode recording of Silicon Zombies Podcast by Nick Larson with Peter Walker, Keith Teare, and Alexander Johnson representing Carta, SignalRank and Velvet. The discussion was entreaging, focusing on the "The Future of Funding" . Sharing valuable findings and data on VC, IPO's and and how #AI is shifting data analysis, workflows and more ! Zain Kuwait Vibranium Venture Capitalp Zamir Shukho, MBA Saad Al Jassar #ZainGreatIdea

For all my fellow founders and CEOs out there. Check out this fantastic opportunity to apply and participate in the 2nd cohort of CancerX Moonshot! Apply!! Especially if your startup is in the pediatric oncology space. #cancermoonshots

This would be transformative!

Very critical for how healthcare will be delivered in the near future. #curiva #gynecologiccancers #breastcancerawarenessmonth #womenofscience

A very exciting new partnership between Moffitt and AZ. Bringing patients new cell therapies faster. Together.

As we reflect on the first half of 2024, it's encouraging to see the strides we've made in the world of women’s health. This momentum give us a renewed sense of purpose and energy as we move into the second half of the year.   This year has already been uplifting, and I'm excited to share some key highlights from a recent Forbes article that underscore the progress and innovation happening in our field:   🔹 $679.48M raised by women’s health companies in H1 2024, setting a new midyear record. 🔹 $12.58M: the highest average deal size seen in recent years. 🔹 A significant increase in $50M+ fundraising rounds, reflecting growing confidence in this sector.   These achievements are in alignment with the White House's Executive Order on Advancing Women's Health and the unwavering support of leaders across the ecosystem.   However, according to the author of the article, Eva Epker, Director of Marketing at Avestria Ventures, “Since 2019, an average of 2.1% of the VC funding invested in healthcare companies has gone to women’s health companies by the half-year point and an average of 2.7% has gone to them by the year’s end. In 1H 2024, women’s health companies received about 2.5% of this funding". Although this is moving in the right direction, it is still a very small percent of VC funding – which is why WHAM is focused on doubling that number through our 3Not30 goals and innovative partnerships.   We all need to advocate for equitable funding and support for women’s health, recognizing the vast potential within this field. How else will we ensure that this upward trend not only continues, but flourishes?   Image Credit: Getty https://lnkd.in/eseFi5AP   #WomensHealth #HealthcareInnovation #WHAMNow #3Not30 #HealthEquity

What a fantastic way to wrap up this chapter of graduating Curiva as a CancerX Moonshot inaugural startup last week in Boston!! Stay tuned for what lies ahead with our amazing champions Moffitt Oncology Network and Atrium Health! Thank you to the entire CancerX Moonshot team and the MassChallenge folks who made this accelerator an extraordinary experience for us and our team. Onwards and Upwards! "If you know you are on the right track, if you have this inner knowledge, then nobody can turn you off... no matter what they say." ~Barbara McClintock - Nobel-Prize-winning geneticist, the first (and, so far, only) woman to win an unshared prize in Physiology or Medicine. 👩🔬 🔬 ⚕

What a fantastic way to wrap up this chapter of graduating Curiva as a CancerX Moonshot inaugural startup last week in Boston!! Stay tuned for what lies ahead with our amazing champions Moffitt Oncology Network and Atrium Health! Thank you to the entire CancerX Moonshot team and the MassChallenge folks who made this accelerator an extraordinary experience for us and our team. Onwards and Upwards! "If you know you are on the right track, if you have this inner knowledge, then nobody can turn you off... no matter what they say." ~Barbara McClintock - Nobel-Prize-winning geneticist, the first (and, so far, only) woman to win an unshared prize in Physiology or Medicine. 👩🔬 🔬 ⚕